J-WDMC Precision Therapeutics 

Tumor-Specific Universal Cancer Drugs 

Tumor-Specific Universal Cancer Drugs that do Not Bind to Normal Tissues

        Our invention “Tumor-Specific-Targeting-Platform” specifically target tumor, does not bind to normal tissues: It is low toxicity to patients. Its low DLT (dose-limiting toxicity) can maximize drug dose and therapy efficacy.  It can reduce cancer therapy-induced patient death, side-effects, complex diseases, lifespan shortening & secondary cancers.

          In comparison, current anticancer drugs/CAR-T targeting to CEACAM5, CEACAM6, Nectin-4, BCMA, CD19, CD20, CD30, CD38, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, FRα, EGFR, Caprin-1, GPC3, Integrin, PD-L1, Trop2, CLDN18.2, PSMA, HER2, HER3, DLL3, TIGIT, PTK7, VEGF, c-Met, B7-H3, & B7-H4…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Roche, & Takeda…etc., show strong binding to normal tissues. These drugs can lead to severe organ damages and life-threatening toxicities. Also, their high DLTs limit drug dose in patients, thus they have low therapy efficacies.

        Many failed/discontinued clinical trials of current ADC drugs targeting to CD47, TIGIT, DLL3, HER2, HER3, Integrin, PTK7, FRα, CD44v6, PD-L1, EGFR, Nectin4, CD70, Trop2, PSMA, CEACAM5, CD73, VEGF, c-Met, and B7-H3…etc., were reported due to severe toxicity and limited efficacy in patients.

    We filed patents in 2026 to get 20+7 years patent protection in most countries worldwide. Utility of our platform:

1.      Antibody-image-guided precision cancer surgery.

2.      Antibody-image-guided precision external beam radiation therapy (EBRT).

3.      Antibody-targeted agent for Boron Neutron Capture Therapy (BNCT).

4.      Antibody-targeted proton and heavy-ion therapy.

5.      Antibody-contrast-enhanced CT, MRI, & PET tumor imaging. 

6.      CAR-T therapy and CAR-NK therapy.

7.      Antibody-cell conjugates (ACCs).

8.      T-cell receptor-mimic (TCRm) antibodies.

9.      Bispecific T-cell Engagers (BiTEs): bispecific antibody for cancer immunotherapy.

10.  Degrader-Antibody Conjugates (DACs) for targeted protein degraders to kill tumors.

11.  Antibody-drug conjugates (ADCs), antibody radio-drug conjugate (ARC), peptide-drug conjugates.

12.  Cancer vaccines: DNA, RNA, protein, & peptide cancer vaccines.

13.  Nanoparticles for targeted magnetic hyperthermia therapy & in situ vaccination.

14. Antibody-targeted ultrasound cancer therapy.

15.  Antibody-image-guided precision Interventional Oncology Therapy.

Tumor-Specific Targeting Platform-Guided Precision Interventional Oncology:

(1) Ablation:  Microwave, Radiofrequency, Cryoablation

(2) Chemoembolization

(3) Radioembolization

(4) Combined with in situ vaccination agent delivering

Advantages:

1.          Tumor-Specific, precision interventional oncology, maximize therapy efficacy.

2.          Does not bind to normal tissues, minimize normal tissues damage.

3.          Capable of treating adenoma, early & late stage tumors. 

4.          Capable of treating most cancer types.

Competitive Analysis:

Current Imaging-guided interventional oncology targeting CEA, PSMA, Mesothelin, VEGFR-2, FRα, SSTR, or 18F-FDG (glucose metabolism) have limitations including: target heterogeneity, off-target physiological uptake, low-resolution limits for tiny lesions, and normal tissues also express these markers. The dye Pegulicianine has 49.1% sensitivity and 86.5% specificity in breast tumor surgery imaging.

Contact: info@j-wdmc.com